Plasma Cytokine Levels in Tanzanian HIV-1-Infected Adults and the Effect of Antiretroviral Treatment

2009 ◽  
Vol 52 (4) ◽  
pp. 493-497 ◽  
Author(s):  
Judith M Haissman ◽  
Lasse S Vestergaard ◽  
Samuel Sembuche ◽  
Christian Erikstrup ◽  
Bruno Mmbando ◽  
...  
Keyword(s):  
Antiretroviral Treatment ◽  
Plasma Cytokine ◽  
Cytokine Levels ◽  
Hiv 1

scholarly journals Plasma Cytokine Levels in Chronic Asymptomatic HIV-1 Subtype C Infection as an Indicator of Disease Progression in Botswana: A Retrospective Case Control Study

2016 ◽  
Vol 32 (4) ◽  
pp. 364-369 ◽  
Author(s):  
Thato Iketleng ◽  
Sikhulile Moyo ◽  
Simani Gaseitsiwe ◽  
Balthazar Nyombi ◽  
Rebecca M. Mitchell ◽  
...  
Keyword(s):  
Disease Progression ◽  
Case Control Study ◽  
Case Control ◽  
Subtype C ◽  
Retrospective Case ◽  
Plasma Cytokine ◽  
Cytokine Levels ◽  
Hiv 1 ◽  
Control Study ◽  
Asymptomatic Hiv

scholarly journals Cytokine profiles in highly active antiretroviral treatment non-adherent, adherent and naive HIV-1 infected patients in Western Kenya

2021 ◽  
Vol 21 (4) ◽  
pp. 1584-92
Author(s):  
Fauzia Musa ◽  
Nathan Shaviya ◽  
Fidelis Mambo ◽  
Collins Abonyo ◽  
Erick Barasa ◽  
...  
Keyword(s):  
Inflammatory Cytokine ◽  
Antiretroviral Treatment ◽  
Healthy Controls ◽  
Highly Active ◽  
Cytokine Balance ◽  
Tnf Α ◽  
Cytokine Levels ◽  
Anti Inflammatory ◽  
Anti Inflammatory Cytokine ◽  
Hiv 1

Background: Cytokines play an important role in signaling the immune system to build an adequate immune responseagainst HIV. HIV distorts the balance between pro and anti-inflammatory cytokines causing viral replication. Highly active antiretroviral treatment (HAART) acts by trying to restore pro and anti-inflammatory cytokine balance. It is not clear how HAART non-adherence influences circulating cytokine levels. This study therefore determined cytokine levels in HAART non-adherent individuals. Methods: This cross-sectional study recruited 163 participants (51 controls, 23 HIV-1+ HAART naive, 28 HAART-adherent6 months, 19 HAART-adherent 12 months and 42 HAART non-adherent). Cytokines were analyzed by ELISA while CD4 T cells determined in 3.0 μl of whole blood using BD FACSCaliburTM and viral load in 0.2ml plasma sample using Abbott Molecular m2000sp sample preparation and m2000rt real-time amplification and detection systems (Abbott MolecularInc., Illinois, USA) according to the manufacturer’s methods. Results: IL-4, IL-6, IL-10, TNF-α and TGF-β were significantly elevated in HIV-1 HAART non-adherent compared withHIV-1 HAART adherent and healthy controls P<0.01. IFN- γ was significantly decreased in HIV-1 HAART non-adherentcompared with HIV-1 HAART adherent and healthy controls P<0.01. TNF-α and TGF-β were significantly reduced in HIV-1 HAART adherent patients at 12 months compared to those at 6 months P<0.01. IL-4 and IL-10 correlated positively withviral load. IL-4, IL-6, IL-10, TNF-α and TGF- β associated inversely with CD4 T cell counts and body mass index (BMI). Conclusion: This study established that HAART adherence is immunologically beneficial to the pro and anti-inflammatory cytokine balance milieu while non-adherence appears to cause alterations in pro and anti-inflammatory cytokines warping the balance in this dichotomy. Keywords: Cytokines; non-adherence; HAART.

scholarly journals Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression

AIDS ◽  
2010 ◽  
Vol 24 (6) ◽  
pp. 819-831 ◽  
Author(s):  
Lindi Roberts ◽  
Jo-Ann S Passmore ◽  
Carolyn Williamson ◽  
Francesca Little ◽  
Lisa M Bebell ◽  
...  
Keyword(s):  
Disease Progression ◽  
Hiv Disease ◽  
Plasma Cytokine ◽  
Cytokine Levels ◽  
Acute Hiv ◽  
Hiv 1

Comparison of plasma cytokine levels in African patients with HIV-1 and HIV-2 infection

AIDS ◽  
1994 ◽  
Vol 8 (7) ◽  
pp. 879-884 ◽  
Author(s):  
Sylvie Chollet-Martin ◽  
Francois Simon ◽  
Sophie Matheron ◽  
Charles Alexandre Joseph ◽  
Carole Elbim ◽  
...  
Keyword(s):  
Plasma Cytokine ◽  
Cytokine Levels ◽  
African Patients ◽  
Hiv 1

scholarly journals Plasma Cytokine Levels and Risk of HIV Type 1 (HIV-1) Transmission and Acquisition: A Nested Case-Control Study Among HIV-1–Serodiscordant Couples

2014 ◽  
Vol 211 (9) ◽  
pp. 1451-1460 ◽  
Author(s):  
Erin M. Kahle ◽  
Michael Bolton ◽  
James P. Hughes ◽  
Deborah Donnell ◽  
Connie Celum ◽  
...  
Keyword(s):  
Case Control Study ◽  
Case Control ◽  
Serodiscordant Couples ◽  
Plasma Cytokine ◽  
Cytokine Levels ◽  
Hiv Type 1 ◽  
Nested Case Control ◽  
Hiv 1 ◽  
Control Study

Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?

Aids Reviews ◽  
2017 ◽  
Vol 19 (4) ◽  
Author(s):  
Valentina Svicher ◽  
Giulia Marchetti ◽  
Adrianna Ammassari ◽  
Francesca Ceccherini-Silberstein ◽  
Loredana Sarmati ◽  
...  
Keyword(s):  
Antiretroviral Treatment ◽  
Treatment Success ◽  
Virological Suppression ◽  
Evaluation And Monitoring ◽  
Hiv 1

scholarly journals Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington’s Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31

2021 ◽  
Author(s):  
Danielle A. Simmons ◽  
Brian D. Mills ◽  
Robert R. Butler III ◽  
Jason Kuan ◽  
Tyne L. M. McHugh ◽  
...  
Keyword(s):  
Mouse Model ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Treatment Response ◽  
Diffusion Tensor ◽  
Disease Onset ◽  
Therapeutic Effects ◽  
Plasma Cytokine ◽  
Cytokine Levels ◽  
Pharmacodynamic Biomarkers

AbstractHuntington’s disease (HD) is caused by an expansion of the CAG repeat in the huntingtin gene leading to preferential neurodegeneration of the striatum. Disease-modifying treatments are not yet available to HD patients and their development would be facilitated by translatable pharmacodynamic biomarkers. Multi-modal magnetic resonance imaging (MRI) and plasma cytokines have been suggested as disease onset/progression biomarkers, but their ability to detect treatment efficacy is understudied. This study used the R6/2 mouse model of HD to assess if structural neuroimaging and biofluid assays can detect treatment response using as a prototype the small molecule p75NTR ligand LM11A-31, shown previously to reduce HD phenotypes in these mice. LM11A-31 alleviated volume reductions in multiple brain regions, including striatum, of vehicle-treated R6/2 mice relative to wild-types (WTs), as assessed with in vivo MRI. LM11A-31 also normalized changes in diffusion tensor imaging (DTI) metrics and diminished increases in certain plasma cytokine levels, including tumor necrosis factor-alpha and interleukin-6, in R6/2 mice. Finally, R6/2-vehicle mice had increased urinary levels of the p75NTR extracellular domain (ecd), a cleavage product released with pro-apoptotic ligand binding that detects the progression of other neurodegenerative diseases; LM11A-31 reduced this increase. These results are the first to show that urinary p75NTR-ecd levels are elevated in an HD mouse model and can be used to detect therapeutic effects. These data also indicate that multi-modal MRI and plasma cytokine levels may be effective pharmacodynamic biomarkers and that using combinations of these markers would be a viable and powerful option for clinical trials.

Sign in / Sign up

Export Citation Format

Share Document